Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cipla, Mannkind, Pilatus, Sanofi, Santhera, Theratechnologies.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, ADC, Anaptysbio, Arrowhead, Astria, Candel, Dizal, Ionctura, Minoryx, Moberg, Pharming, Q32, Horizon, Scilex, Siga, Sound, Spruce.

Biopharmas raising money in public or private financings, including: Ambrosia, Angitia, Biovaxys, Cellectis, Chroma Medicine, Immunitybio, Merck, Nchroma, Nvelop, Okogen, Tasca, Veradermics.

New hires and promotions in the biopharma industry, including: Cosmo, Invea, Zentalis.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aliada, Asahi Kasei, Bayer, Biopath Holdings, Cellactar, Chiome, Hepion, Hong Kong King-Friend Industrial, Immunogenesis, Meitheal, Moberg, Monte Rosa, Novartis, Negev Labs, Pharma Two B, Phathom, Polypid, VBI Vaccines.

Nearly three years after being terminated as president and CEO of Cytodyn Inc., Nader Pourhassan was convicted June 9 by a U.S. federal jury for his role in a securities fraud scheme to deceive investors about the Vancouver, Wash.-based company’s development of leronlimab. The jury also convicted Kazem Kazempour, the CEO of Amarex Clinical Research LLC, a contract research organization hired by Cytodyn, for his part in the scheme.

CNS specialist Noema Pharma AG has added a further $44 million to its series B, bringing the total for the round to $147 million. The new financing bolsters the balance sheet as the Basel, Switzerland-based company progresses four phase II trials, with key data readouts expected in 2025.